DarioHealth (DRIO) to Release Quarterly Earnings on Monday

by · The Cerbat Gem

DarioHealth (NASDAQ:DRIO – Get Free Report) is projected to post its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect DarioHealth to post earnings of ($1.57) per share and revenue of $5.0480 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, March 9, 2026 at 8:30 AM ET.

DarioHealth Trading Down 2.9%

Shares of NASDAQ:DRIO opened at $9.70 on Friday. The firm has a market cap of $65.55 million, a P/E ratio of -0.87 and a beta of 1.08. DarioHealth has a twelve month low of $5.93 and a twelve month high of $17.74. The company has a current ratio of 4.55, a quick ratio of 4.02 and a debt-to-equity ratio of 0.41. The company has a 50 day moving average of $11.27 and a 200-day moving average of $11.78.

Hedge Funds Weigh In On DarioHealth

A number of hedge funds have recently modified their holdings of DRIO. Kestra Advisory Services LLC acquired a new stake in DarioHealth in the 4th quarter valued at $35,000. XTX Topco Ltd raised its stake in DarioHealth by 229.0% during the second quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock worth $42,000 after acquiring an additional 43,513 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of DarioHealth by 167.9% during the fourth quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock valued at $564,000 after acquiring an additional 31,063 shares during the period. 33.39% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Wall Street Zen downgraded DarioHealth from a “hold” rating to a “sell” rating in a research report on Sunday, January 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of DarioHealth in a research report on Monday, December 29th. TD Cowen reaffirmed a “hold” rating on shares of DarioHealth in a report on Friday, November 14th. Finally, Stifel Nicolaus set a $16.00 price target on DarioHealth in a research report on Friday, November 14th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $38.00.

View Our Latest Stock Report on DarioHealth

About DarioHealth

(Get Free Report)

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.

Featured Articles